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The striatum harbors two neuronal populations that enable action selection. One
population represents the striatonigral pathway, expresses the dopamine receptor D1
(DRD1) and promotes the execution of motor programs, while the other population
represents the striatopallidal pathway, expresses the dopamine receptor D2 (DRD2)
and suppresses voluntary activity. The two populations integrate distinct sensorimotor,
cognitive, and emotional information streams and their combined activity enables the
selection of adaptive behaviors. Characterization of these populations is critical to the
understanding of their role in action selection, because it aids the identification of the
molecular mechanisms that separate them. To that end, we used fluorescent in situ
hybridization to quantify the percentage of striatal cells that (co)express dopaminergic
receptors and receptors of the cannabinoid, melanocortin or opioid neurotransmitters
systems. Our main findings are that the cannabinoid 1 receptor is equally expressed on
both populations with a gradient from dorsal to ventral striatum, that the opioid receptors
have a preference for expression with either the DRD1 or DRD2 and that the melanocortin
4 receptor (MC4R) is predominantly expressed in ventral parts of the striatum. In addition,
we find that the level of MC4R expression determines its localization to either the DRD1
or the DRD2 population. Thereby, we provide insight into the sensitivity of the two
dopaminoceptive populations to these neurotransmitters and progress the understanding
of the mechanisms that enable action selection.
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INTRODUCTION
To ensure survival, an organism needs to select adaptive behav-
iors from its behavioral repertoire. One neural network that is
involved in action selection is the basal ganglia, which consists of
several subcortical structures (Mogenson et al., 1980). The input
nucleus of the basal ganglia is the striatum (Smith et al., 1994;
Kincaid et al., 1998; Bolam et al., 2000), a brain area in which
GABAergic projection neuronsmake up for more than 95% of the
cellular identity (Kreitzer, 2009). These medium spiny neurons
(MSNs) can be divided into two classes, based on the expres-
sion of either the dopamine receptor D1 (D1R) or the dopamine
receptor D2 (D2R) (Gerfen et al., 1990; Le Moine and Bloch,
1995).
Both cellular populations influence the activity of the
output nucleus of the basal ganglia; the internal globus
pallidus/substantia nigra reticular part (GPi/SNpr) complex.
The D1R population sends inhibitory projections to the
Gpi/SNpr complex directly, while the D2Rpopulation activates
the GPi/SNpr complex indirectly, via the external globus pallidus
and the subthalamic nucleus (STN) (Gerfen, 1992; Kawaguchi,
1997; Gerfen and Surmeier, 2011). Activity of the GPi/SNpr
is thought to exert control over voluntary movement by send-
ing inhibitory signals to thalamic and brain stem nuclei. Much
attention has been directed toward the existence of the antag-
onistic D1R and D2R populations that drive GPi/SNpr activity
(Alexander et al., 1986; Graybiel, 2000), because they are the phys-
ical representation of an important concept in the neurosciences:
the “go-no go” pathway. In this model, the D1R population
represents “go” as it inhibits the GPi/SNpr, while the D2R rep-
resents “no go” as it activates the GPi/SNpr. Activity of the
D1R population is thought to promote the execution of motor
programs, while activation of the D2R population suppresses vol-
untary movement (Gerfen and Surmeier, 2011). While it is far
from clear how these two populations work together to select
adaptive behaviors, combined activity of these populations has
been suggested to enable the execution of one particular motor
program, by simultaneous suppression of competing motor pro-
grams (Mink, 2003; Cui et al., 2013).
In search of the molecular mechanisms that separate the two
MSN populations and enable the selection of adaptive behav-
iors, the focus should not be limited to the dopaminergic system
only, as dopaminergic receptors are not the only G-protein cou-
pled receptors (GPCR) whose expression is limited to either of
the two MSN populations. In addition, some neuropeptides are
differentially expressed in the two MSN populations as well: D1R
neurons exclusively express the acetylcholine muscarinic recep-
tor 4 and substance P (Gerfen and Young, 1988; Bernard et al.,
1992; Ince et al., 1997), while expression of the adenosine recep-
tor 2a (A2aR) and enkephalin is limited to the D2R population
(Gerfen and Young, 1988; Schiffmann et al., 1991). Moreover, it
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should be noted that the striatum can be divided into separate
functional regions that process distinct information streams and
are aligned to a gradient that is organized in a dorsolateral to ven-
tromedial fashion (Voorn et al., 2004). Dorsolateral regions are
primarily involved in the processing of sensorimotor informa-
tion (Albin et al., 1989; Graybiel et al., 1994; Chang et al., 2002;
Haber, 2003; Balleine et al., 2007; Durieux et al., 2012), central
regions mediate cognitive functions such as procedural learning
and working memory (Phillips and Carr, 1987; Jog et al., 1999),
while ventromedial parts are associated with the integration of
motivational state (Kelley and Domesick, 1982; Kelley et al., 1982;
McGeorge and Faull, 1989; Cardinal et al., 2002). As separate
striatal regions process different information streams, it is to be
expected that they show differences in cellular identity, which
could arise through the innervation of distinct neurotransmitter
systems. Therefore, the location and instances of (co)expression
of their receptors can serve to mark differences in cellular iden-
tity and aids the understanding of the molecular mechanisms that
enable striatal functioning.
To that end, we here used fluorescent in situ hybridization
(FISH) to investigate the (co)expression of dopamine receptor
D1 (DRD1) and the dopamine receptor D2 (DRD2) mRNAs with
transcripts of the GPCRs of the cannabinoid, melanocortinergic
and opioid neurotransmitter systems. We quantified expression
levels in five different areas, the lateral and medial caudate puta-
men (lCPu, mCPu), the nucleus accumbens core and shell (AccC
and AccSh) and the olfactory tubercle (OT), which is thought
to share functionality with the nucleus accumbens (Ikemoto,
2007). These neurotransmitter systems are known to modulate
the activity of MSNs in conjunction with dopaminergic neu-
rotransmission and visualization of their receptors might mark
cellular subpopulations in the striatum. In doing so, we provide
insight into the cellular architecture of the striatum and progress
the understanding of its role in action selection.
MATERIALS AND METHODS
ANIMALS
Adult male Wistar rats (Charles-River, Erkrath, Germany) were
used (n = 2). The animals were housed individually (378 ×
217 × 180 cm) in a controlled environment under a 12:12
light/dark cycle with lights on at 0700 h. The experiments were
approved by the Animal Ethics Committee of the University
Medical Center Utrecht, according to Dutch legislation.
FISH PROBES
The probe sets used to detect the desired rat mRNAs are designed
by Panomics (Santa Clara, USA), using published sequences (see
Table 1). Blast searches were performed to avoid large homolo-
gous sequences of undesired genes and guarantee probe speci-
ficity. The probe sets consist of about 20 probe pairs, with each
probe having a length of 20–25 nucleotides. The probes within
each pair are designed to hybridize at adjacent regions of the tar-
get mRNA, allowing the hybridization of a preamplification oligo
(Panomics) that spans the hybridized probe pair, thus ensuring
signal specificity. This specific signal was further amplified by
hybridization of amplification oligo’s (Panomics) and visualized
by label oligo’s (Panomics), resulting in an amplification of up to
Table 1 | Regions and accession numbers used for synthesis of the
FISH probes.
Gene Accession number Region
DRD1 NM_012546 29-2164
DRD2 NM_012547 410-1488
CB1R NM_012784 175-1120
MC4R NM_013099 231-1136
MC3R NM_001025270 198-1076
MOR NM_013071 226-1228
DOR NM_012617 120-1095
KOR NM_017167 133-1162
A2aR NM_053294 504-1611
ENK NM_017139 21-1036
SubP NM_012666 89-940
500 times for low abundantmRNAs. In addition, probe pairs were
designed to hybridize at adjacent sections, covering the entire
region that is mentioned in Table 1. Other probes were designed
to hybridize to small regions within the desired gene sequence that
share homology with undesired gene sequences. These probes did
not allow hybridization of preamplification oligo’s, which ensured
specificity of the amplified signal.
FISH PROCEDURE
After decapitation, brains were isolated and immediately frozen
on dry ice. Coronal sections (16μm) were made with a Leica
CM 3050 cryostat between 1.38 and 1.70mm anterior to bregma
(Leica, Wetzlar, Germany). First, sections were post-fixed in 4%
paraformaldehyde for 10min, washed in phosphate buffered
saline (PBS) and acetylated for 10min. After washing, sections
were subsequently incubated for 2 h in prehybridization mix
(50% deionized formamide, 5× SSC, 5× Denhardt’s solution,
250μg/ml tRNA baker’s yeast, 500μg/ml sonicated salmon sperm
DNA final concentrations in MilliQ). Next, sections were incu-
bated overnight at 40◦C in 120μl hybridization mix (Panomics)
containing the probe sets (DRD1 1:33, DRD2 1:33, other probes
1:50) and washed. Subsequently, sections were incubated for
1.5 h at 40◦C in 120μl PreAmplifier Mix (Panomics) contain-
ing preamplification oligo’s (PreAmp TYPE4 1:20, PreAmp TYPE
6 1:50, PreAmp TYPE 8 1:33) and washed. Then, sections were
incubated for 1.5 h at 40◦C in 120μl Amplifier Mix (Panomics)
containing amplification oligo’s (Amp TYPE4 1:20, Amp TYPE 6
1:50, Amp TYPE 8 1:33) and washed. Next, sections were incu-
bated for 1.5 h at 40◦C in 120μl in Label Probe Mix (Panomics)
containing label oligo’s (LP TYPE4 1:20, LP TYPE 8 1:33, LP
TYPE 6 1:50). After washing, sections were incubated in 750μl
PBS supplemented with 4’,6-diamidino-2-phenylindole (DAPI)
(6.7μg/ml, Sigma Aldrich, St. Louis, USA) for 5min. Finally,
sections were washed and embedded in Mowiol.
IMAGE ACQUISITION
Images were obtained with a Zeiss AxioScope A1 microscope
(Carl Zeiss, Jena, Germany) equipped with Chroma filter sets
(Chroma, Bellows Falls, USA) and Zeiss AxioVision Rel. 4.8
acquisition software. DAPI was acquired using the 31000v2 filter
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block of Chroma. The Chroma FITC filter block 410001 was used
to acquire the 488 nm conjugated TYPE4 label. The 550 nm con-
jugated TYPE8 label was acquired using a Chroma TRITC 41002b
filter block containing a narrowband excitation filter. A custom
Chroma Cy5 infrared filter was used for the acquisition of the
650 nm conjugated TYPE6 label. This label was excited at 650 nm
using an HQ650/45x filter (Chroma) and light was directed by
a Q680LP dichroic mirror (Chroma) through a HQ690LP emis-
sion filter (Chroma). Images were processed and analyzed using
ImageJ 1.43r software.
DATA ANALYSIS
The (co)expression of the mRNA transcripts of the different
GPCRs and neuropeptides was quantified in five different areas
of the striatum: the lateral caudate putamen (lCPu), the medial
caudate putamen (mCPu), the nucleus accumbens core (AccC),
the nucleus accumbens shell (AccSh) and the olfactory tubercle
(OT). Four images (300 × 220μm) per striatal area were used for
quantification of a certain mRNAwith theDRD1 andDRD2 tran-
scripts. Separate cells were identified on the basis of nuclear DAPI
staining and were counted as expressing a certain mRNA if one
or more fluorescent dots were present in, or in close vicinity of
(defined as a circle with twice the diameter of the DAPI staining)
the area of DAPI staining.
The percentage of cells expressing a certain mRNA was deter-
mined by dividing the amount of cells expressing a certain mRNA
by the total amount of DAPI stained nuclei (= number of cells
expressing a certain mRNA/the total number of DAPI stained
nuclei∗100). Statistical analyses were done by conduction of the
non-parametric Kruskal–Wallis tests, with significance levels set
at α = 0.05, to determine significant differences in levels of
expression per striatal area in SPSS 20 for Windows (IBM, USA).
The Kruskal–Wallis test was used because the small sample sizes
did not allow for any inferences on the underlying distributions.
The percentage of cells expressing DRD1 mRNA and another
mRNA was determined by dividing the amount of cells positive
for DRD1 and another mRNA by the total amount of DRD1
positive cells (number of cells expressing DRD1 and another
mRNA/total number of cells expressing DRD1∗100). An identi-
cal approach was used for calculation of the percentage of DRD2
expressing cells that also expressed another mRNA. Because of
the small sample sizes, the preference for expression of a certain
mRNAwith transcripts of eitherDRD1 orDRD2were determined
by conduction of non-parametric Mann–Whitney U tests in SPSS
20 for Windows (IBM, USA). For these tests, results from sep-
arate striatal areas were combined, as individual tests for each
separate striatal area would necessitate corrections for multiple
comparisons and essentially yield comparable results.
To determine if cells were either high- or low-expressing, the
number of fluorescent dots were counted and cells were arbitrarily
classified as low expressing cells if they expressed less than 30 dots
and classified as high expressing in all other instances.
RESULTS
COEXPRESSION OF DRD1 AND DRD2 WITH A2aR, ENK OR SubP
We quantified the coexpression of genes that are known to
segregate to either the D1R or D2R population (see Table 2).
Table 2 | Percentage of coexpression of all investigated mRNAs with
Drd1 or Drd2 transcripts.
Gene Expression with Drd1 (%) Expression with Drd2 (%)
A2aR 0.39± 0.15 98.72± 0.33
CB1R 39.765± 7.34 36.66± 7.07
DOR 0.78± 0.31 70.27± 6.30
DRD1 100± 0.00 0.14± 0.01
ENK 3.41± 1.12 95.27± 0.93
MC3R None observed None observed
MC4R 12.93± 3.25 10.94± 2.45
MOR 8.30± 1.66 3.70± 1.01
KOR 25.34± 2.54 6.38± 1.19
SubP 92.33± 1.49 2.32± 0.51
For the D1R population, this entailed quantification of coex-
pression of DRD1 mRNAs with mRNAs of the precursor to
substance P, protachykinin-1 (SubP). For the D2R population
this entailed quantification of coexpression of DRD2 mRNAs
with mRNAs of the genes A2aR and the precursor to the
opioid neuropeptide enkephalin, proenkephalin (ENK). DRD1
was virtually not expressed in any DRD2 expressing cell, as
only 0.13 ± 0.08% of DRD1 expressing cells also expressed
DRD2 (z = −6.054, p < 0.001) (Figures 1A,D,I, 2D and 3D).
As expected, A2aR showed a preference for coexpression with
DRD2 (z = −5.553, p < 0.001) (Figures 1B,C,E,F,I), as 0.39 ±
0.15% of DRD1 expressing cells expressed A2aR, while 98.72
± 0.33% of cells positive for DRD1 expressed A2aR. Specificity
was also observed for expression of DRD2 with ENK (z =
−5.425, p < 0.001) (Supplementary Figures 1A–H), as only
3.41 ± 1.12% of DRD1 cells and 95.27 ± 0.93% of DRD2
cells expressed ENK. SubP showed a preference for colocaliza-
tion with DRD1 (z = −5.424, p < 0.001), as 92.33 ± 1.49% of
DRD1 cells expressed SubP, while only 2.32 ± 0.51% of DRD2
cells expressed SubP (Supplementary Figures 2A–H). DRD1,
DRD2, and A2aR were expressed evenly in all striatal areas
(Figures 1G,H). Finally, DRD1 was expressed in 33.75 ± 1.02%
of all striatal cells, whileDRD2 was expressed in 25.17 ± 0.82% of
striatal cells, which was significantly less (z = −4.748, p < 0.001)
(Figure 1H).
COEXPRESSION OF DRD1, DRD2 AND CANNABINOID RECEPTOR 1
Striatal areas differentially expressed mRNA transcripts of the
cannabinoid receptor 1 (CB1R) (χ2 = 11.984, df = 4, p =
0.017), as the highest percentage of CB1R positive cells was
found in the lCPu (55.05 ± 2.61%), while lower amounts
of CB1R positive cells were observed in the other parts of
the striatum (mCPU: 20.65 ± 6.15%, AccC: 12.30 ± 1.91%,
AccSh: 13.85 ± 3.17% and OT: 9.5 ± 1.40%), forming a
decreasing dorsolateral to ventromedial gradient (Figure 2G).
The CB1R showed no preference for coexpression with
mRNAs of either of the two dopaminergic GPCRs, as
39.765 ± 7.34% of DRD1 expressing cells and 36.66 ± 7.07%
of DRD2 cells expressed CB1R (Figures 2A–C,E,F,H). In addi-
tion, the amount of CB1R expression per cell was also
dependent on striatal area, as high expressing cells were
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FIGURE 1 | Coexpression of the adenosine 2a receptor with both
DRD1 and DRD2. (A–F) Example of staining in the lateral caudate
putamen (lCPu). Nuclei were stained using 4′,6-diamidino-2-phenylindole
(DAPI) (blue). Clear expression for the dopamine receptor D1 (DRD1) (A),
the dopamine receptor D2 (DRD2) (B) and the adenosine 2a receptor
(A2aR) (C). White bar, 25μm. (D,E) Virtually no coexpression was found
for DRD1 and DRD2 and for DRD1 and A2aR. (F) Clear coexpression
was found for DRD2 and A2aR. (G) Quantification of expression and
coexpression was performed in several regions of the striatum: 1 =
lCPu, 2 = medial caudate putamen (mCPu), 3 = nucleus accumbens
core (AccC), 4 = nucleus accumbens shell (AccSh), 5 = olfactory
tubercle (OT). Picture adapted from Voorn et al. (2004). (H) Quantification
of the expression of DRD1, DRD2 and A2aR. Bars represent the mean
percentage (+s.e.m.) of DAPI stained nuclei that are positive for DRD1,
DRD2 or A2aR, where “&” indicate a significant difference of p < 0.05 in
the mean percentage of DRD1 positive cells compared to DRD2 positive
cells (as determined by the Mann–Whitney U test). (I) Quantification of
coexpression of DRD1, DRD2, and A2aR. Bars represent the mean
percentage (+s.e.m.) of cells expressing DRD1 also expressing DRD2,
the percentage of DRD1 expressing cells also expressing A2aR and the
percentage of DRD2 expressing cells also expressing A2aR, where “∗”
indicates a significant difference of p ≤ 0.05 in the percentage of cells
that coexpress DRD1 and A2aR compared to cells that coexpress DRD2
and A2aR (as determined by the Mann–Whitney U test).
predominantly found in the lCPu and low expressing cells
in other parts of the striatum (Figures 2I–M). Also here,
the DRD1 and DRD2 populations were segregated, as we
found that only 0.20 ± 0.07% of DRD1 expressing cells
also expressed DRD2 (z = −5.929, p < 0.001) (Figure 2H).
Moreover, significantly more striatal cells expressed DRD1
(34.91 ± 1.24%) than DRD2 (23.17 ± 0.84%) (z = −5.195, p <
0.001) (Figure 2G).
COEXPRESSION OF DRD1 AND DRD2 WITH MELANOCORTIN
RECEPTORS
NomRNA expression of themelanocortin receptor 3 (MC3R) was
found (Supplementary Figure 3), but a clear signal was present for
mRNAs of the melanocortin receptor 4 (MC4R) (Figure 3C) and
MC4R was differentially expressed in striatal areas (χ2 = 17.361,
df = 4, p = 0.002). The highest expression was found in the OT
(21.43 ± 3.84%), when compared to the AccC (8.30 ± 1.83%)
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FIGURE 2 | Coexpression of the cannabinoid receptor 1 with both DRD1
and DRD2. (A–F) Example of staining in the lCPu. Nuclei were stained using
DAPI (blue). Clear expression for the DRD1 (A), DRD2 (B) and cannabiniod 1
receptor (CB1R) (C). White bar, 25μm. (D) No coexpression found for DRD1
and DRD2. (E,F) Clear coexpression for DRD1 and CB1R and DRD2 and
CB1R. (G) Quantification of the expression of DRD1, DRD2 and CB1R. Bars
represent the mean percentage (+s.e.m.) of DAPI stained nuclei that are
positive for DRD1, DRD2, or CB1R, where “&” indicates a significant
difference of p < 0.05 in the mean percentage of DRD1 positive cells
compared to DRD2 positive cells (as determined by the Mann–Whitney U
test). (H) Quantification of coexpression of DRD1, DRD2, and CB1R. Bars
represent the mean percentage (+s.e.m.) of cells expressing DRD1 also
expressing DRD2, the percentage of DRD1 expressing cells also expressing
CB1R and the percentage of DRD2 expressing cells also expressing CB1R.
(I–M) Example pictures of CB1R expression in the five regions defined within
the striatum. White bar, 30μm.
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and AccSh (5.68 ± 1.63%). No MC4R expression was observed in
themCPu and virtually no expression in the lCPu (0.43± 0.24%),
so MC4R mRNA expression gradually decreases ventral to dorsal
parts of the striatum (Figures 3G,I–M). The MC4R showed no
apparent preference for either dopaminergic GPCR, as 12.93 ±
3.25% of DRD1 expressing cells and 10.94 ± 2.45% of DRD2
expressed MC4R (Figures 3A–C,E,F,H), although it was observed
that cells expressing high levels of MC4R also expressed DRD1,
but notDRD2 (Figures 3N–R). Again, theDRD1 andDRD2 pop-
ulations were segregated, as 0.14 ± 0.08% of DRD1 expressing
cells also expressed DRD2 (z = −6.054, p < 0.001) (Figure 3H).
In addition, striatal cells expressed significantly more DRD1
(34.35 ± 1.39%) than DRD2 (20.23 ± 1.03%) (z = −5.384,
p < 0.001) (Figure 3G).
COEXPRESSION OF DRD1 AND DRD2 WITH OPIOID RECEPTORS
Also mRNA transcripts of theμ-opioid receptor (MOR) were dif-
ferentially expressed within the striatum (lCPu: 1.225 ± 0.82%,
mCPu: 3.45± 0.82%, AccC: 6.375± 1.99%, AccSh: 4.95 ± 1.28%
and OT: 1.9 ± 0.85%) (χ2 = 10.928, df = 4, p = 0.027)
(Figure 4G). MOR showed a preference for expression with
the DRD1, as 8.30 ± 1.66% of DRD1 expressing cells and
3.70 ± 1.01% of DRD2 expressing cells also expressed MOR
(z = −2.112, p = 0.035) (Figures 4A,D,H). Transcripts of the
δ-opioid receptor (DOR) were dispersed evenly in striatal areas
(lCPu: 15.55 ± 4.81%, mCPu: 17.03 ± 5.47%, AccC: 13.33 ±
3.91%, AccSh: 18.63 ± 5.78% and OT: 25.85 ± 4.37%)
(Figure 4I).DOR showed a preference for expression withDRD2,
as 0.78 ± 0.31% of DRD1 expressing cells and 70.27 ± 6.30%
of DRD2 expressing cells also expressed DOR (z = −5.530,
p < 0.001) (Figures 4B,E,J). Transcripts of the κ-opioid recep-
tor (KOR) positive cells were differentially expressed in the
striatum (lCPu: 5.175 ± 1.07%, mCPu: 7.93 ± 1.69%, AccC:
10.90 ± 1.85%, AccSh: 14.18 ± 2.60% and OT: 14.85 ± 3.36%)
(χ2 = 10.928, df = 4, p = 0.027), showing a gradual increase in
expression from dorsolateral to ventromedial parts of the stria-
tum (Figure 4K). Moreover, KOR showed a preference for expres-
sion with the DRD1, as 25.34 ± 2.54% of DRD1 expressing cells
and 6.38± 1.19% ofDRD2 expressing cells expressed KOR as well
(z = −4.951, p < 0.001) (Figures 4C,F,L). Also here, the DRD1
andDRD2 populations were segregated, as 0.13± 0.04% ofDRD1
expressing cells also expressed DRD2 (z = −7.554, p < 0.001)
(Figure 3H). In addition, striatal cells did express significantly
more DRD1 (34.35 ± 1.39%) than DRD2 (20.23 ± 1.03%)
(z = −5.384, p < 0.001) (Figure 3G).
DISCUSSION
To the best of our knowledge, we here show for the first time
which percentage of striatal cells express DRD1 and DRD2
mRNAs and transcripts of the cannabinoid, melanocortin or opi-
oid receptors. We first investigated if the expression of genes that
are known to be expressed in only one of the two MSN popula-
tions indeed segregate along these lines. The D1R population is
known to express SubP, while the D2R population can be identi-
fied by expression of ENK (Gerfen and Young, 1988). Moreover,
A2aR is known to inhibit the function of the D2R by the for-
mation of a functional heterodimer (Canals et al., 2003; Azdad
et al., 2009), for which coexpression is a prerequisite (Schiffmann
et al., 1991). Indeed, we observed near specific coexpression of
the transcripts of SubP with DRD1 mRNAs and of ENK and
A2aR transcripts with DRD2 mRNAs.and found very few cells
(<1%) expressing both DRD1 and DRD2. In addition, we found
that striatal cells express DRD1 in higher percentages than DRD2,
which confirmed earlier findings (Bertran-Gonzalez et al., 2008;
Matamales et al., 2009; Gangarossa et al., 2013b).
As stated earlier, a clear distinction in dopaminergic GPCR
expressing populations can be made based on the expression pat-
terns of either the D1R or the D2R (Gerfen et al., 1990; Le Moine
and Bloch, 1995). However, this clear segregation of the D1R
and D2R populations has been subject of much debate (Bertran-
Gonzalez et al., 2010), as a number of groups have reported
DRD1 and DRD2 coexpressing cells and the existence of func-
tional D1R/D2R heterodimers (Larson and Ariano, 1994; Shetreat
et al., 1996; Aizman et al., 2000; Hasbi et al., 2009; Perreault et al.,
2012). These studies should be interpreted with care however, as
the use of striatal cultures, in which neurons are functioning in
an artificial environment, as well as cross-reactivity of the used
antibodies may explain the reported D1R/D2R heterodimers, In
any case, we also found instances of DRD1 and DRD2 coexpres-
sion, in percentages similar to studies using BAC transgenic mice
(Gangarossa et al., 2013b). Moreover, a small overlap of the D1R
and D2R populations is also evidenced by our finding that the
neuropeptides ENK and SubP are expressed in bothMSN popula-
tions. In addition, a recent study suggests that an area between the
AccSh and AccC is an ideal anatomical substrate where D1R/D2R
signaling could take place (Gangarossa et al., 2013a). So, MSNs
might not be completely segregated into a D1R/SubP population
and a D2R/ENK/A2aR population, depending on striatal area.
Future research has to show if and where the two MSN popu-
lations overlap and establish the functional consequences of this
presumed overlap.
Our next focus was on the expression of CB1R in the twoMSN
populations. CB1R mRNA was highly expressed in the dorso-
lateral part of the striatum and its expression decreased toward
ventromedial parts of the striatum, in congruence with earlier
reports (Hermann et al., 2002; Martin et al., 2008). Extending
on these results, we found that the CB1R is promiscuous in its
coexpression with the dopaminergic GPCRs and that nearly all
DRD1 and DRD2 positive neurons expressed the CB1R in the
lCPu, while this percentage was much lower in the ventral stria-
tum. Despite the lower expression of CB1R in the ventral parts
of the striatum, our findings stress the ability of endocannabi-
noids to influence both motor functions and reward processing
(Monory et al., 2007; Ferre et al., 2010). Moreover, our data con-
firm results of earlier studies that showed that the cannabinoid
system is able to give local feedback on the activity of both MSN
populations (for extensive review see: Fitzgerald et al., 2012)
The melanocortinergic system is well known for its role in
the regulation of energy balance, in particular through the action
on its two centrally expressed GPCRs: the MC3R and the MC4R
(Gantz and Fong, 2003). No indication of striatal expression of
MC3R transcripts was found, readily excluding a prominent role
for MC3R signaling in the striatum. Our observations suggest
that themelanocortinergic system primarily interacts with ventral
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FIGURE 3 | Coexpression of the melanocortin 4 receptor with both
DRD1 and DRD2. (A–F) Example of staining in the OT. Nuclei were
stained using DAPI (blue). Clear expression for the DRD1 (A), DRD2
(B), and modest expression for melanocortin 4 receptor (MC4R) (C).
Enlargements of cells are depicted expressing both DRD1 and MC4R,
or both DRD2 and MC4R. White bar, 25μm. (D) No coexpression
found for DRD1 and DRD2. (E,F) Clear coexpression for DRD1 and
MC4R and DRD2 and MC4R. White bar, 25μm. (G) Quantification of
the expression of DRD1, DRD2, and MC4R. Bars
(Continued)
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represent the mean percentage +s.e.m. of DAPI stained nuclei that are
positive for DRD1, DRD2, or MC4R, where “&” indicates a significant
difference of p < 0.05 in the mean percentage of DRD1 positive cells
compared to DRD2 positive cells (as determined by the Mann–Whitney U
test). (H) Quantification of coexpression of DRD1, DRD2, and MC4R. Bars
represent the mean percentage (+s.e.m.) of cells expressing DRD1 also
expressing DRD2, the percentage of DRD1 expressing cells also expressing
MC4R and the percentage of DRD2 expressing cells also expressing MC4R.
(I–M) Example pictures of MC4R expression in the five regions defined
within the striatum. White bar, 30μm. (N–R) Cells expressing high amounts
of MC4R are found in the DRD1 population. White bar, 10μm.
parts of the striatum. Looking at the percentage of coexpression of
MC4R transcripts with either DRD1 or DRD2 transcripts, no sig-
nificant differences were observed. However, the expression levels
of MC4R transcripts correlate with the expression of either the
DRD1 or the DRD2, as high levels of MC4R transcripts coincide
with coexpression of DRD1, but not DRD2 mRNAs. This corre-
lation is of particular interest in light of a number of studies that
reported the involvement of MC4Rs expressed on D1R MSNs in
a range of behavioral phenotypes. Lim et al. have found that the
MC4R mediates stress-induced decreases in the strength of exci-
tatory synapses onto D1R, but not D2R expressing MSNs, as the
MC4R is necessary to internalize AMPA receptors on D1R MSNs
after chronic stress (Lim et al., 2012).Moreover,MC4Rs expressed
on D1RMSNsmediate parts of the phenotype observed inMC4R
null mice, such as increased meal size, insensitivity to cocaine-
induced anorexia and locomotor sensitization and the inability to
be conditioned for high-fat food reinforcers (Cui et al., 2012; Cui
and Lutter, 2013). In addition, the high expression of MC4R on
D1R MSNs could explain why the infusion of MC4R antagonists
blocks the behavioral effects of cocaine, which are thought to be
mediated primarily by D1R signaling (Hsu et al., 2005). Taken
together, these findings indicate that MC4R signaling strongly
modulates D1R signaling, making it an interesting target for phar-
macotherapies to combat psychopathologies such as addiction
and obesity.
Opioids generally act upon three different GPCRs. These
GPCRs differ in opioid affinity and are expressed throughout the
entire striatum (Mansour et al., 1995). We and others observed
high MOR mRNA expression in the AccC and AccSh, imply-
ing a stronger influence of MOR on the nucleus accumbens.
Moreover, we confirmed a gradual increase in the expression of
KOR transcripts from dorsolateral toward ventromedial parts of
the striatum (Mansour et al., 1994) and showed that all inves-
tigated opioid receptors show a preference for expression with
either of the to dopaminergic GPCRs: the DOR showed near
exclusive coexpression with the DRD2, the KOR showed a pref-
erence for coexpression with the DRD1, and the MOR showed a
preference for coexpression with the DRD1.
The main agonist for DOR is enkephalin, for KOR dynor-
phin and for MOR endorphin (Corbett et al., 2006). Dynorphins
and enkephalins are synthesized in DRD1 and DRD2 express-
ing neurons, respectively, (Gerfen et al., 1990), while endorphins
are synthesized in POMC expressing neurons (Corbett et al.,
2006). These observations led us to postulate that dynorphins
and enkephalins are able to give selective feedback on DRD1
and DRD2 expressing neurons, respectively. Since opioid recep-
tors signal via Gi resulting in hyperpolarization via activation of
GIRK channels (Torrecilla et al., 2002), release of opioids from
striatal MSNs may provide an auto-inhibitory feedback loop.
KOR activation has been associated with dysphoria and aversion
(Pfeiffer et al., 1986; Shippenberg et al., 2001), while DOR acti-
vation has been suggested to improve negative emotional states
(Filliol et al., 2000; Ragnauth et al., 2001; Roberts et al., 2001;
Perrine et al., 2006). Also, activation of DOR increases the release
of dopamine in the striatum (Di Chiara and Imperato, 1988),
while KOR activation has the opposite effect (Mulder et al., 1984).
These opposing roles are also reflected in the differential influ-
ence of these opioid receptors on dopamine-related behaviors
(Shippenberg andHerz, 1987; Bals-Kubik et al., 1989). It is tempt-
ing to speculate that this is due to the preference of these receptors
for one of the two MSN populations, but our results are not con-
gruent with results of others, which found DRD1 to coexpress
with DOR in much higher levels than we did (Ambrose et al.,
2006). This might be due to differences in subcellular localization
at the pre- or post-synapse, to internalization of the receptor, to
the striatal region that was under investigation in the other study
(a specific part of the dorsal striatum) or to cross-reactivity of the
antibodies used and future studies will have to clarify this discrep-
ancy. Taken together, our observations suggest thatMOR is able to
modulate the activity of both MSN populations, with a stronger
influence on theDRD1 population, as opposed toDOR and KOR,
which seem to target specific MSN subpopulations.
Although through the quantification of the percentage of stri-
atal cells that express DRD1 and DRD2 mRNAs with transcripts
of cannabinoid, melanocortin or opioid GPCRs this study pro-
vides valuable insight in the cellular architecture of the striatum,
it has two major limitations that should be taken into account.
Firstly, the nature of our methods do not allow for any inference
on the location of the proteins that are translated from the GPCR
mRNAs. As such, we cannot distinguish between pre- and post-
synaptically located GPCRs and thus do not provide the exact
location where endocannabinoids, melanocortins, and opioids
act to modulate MSN activity. Secondly, we only used hemi-
spheres of two different animals in this study. As the majority
of our results are so prominent (the GPCRs under investigation
showed either a clear preference for colocalization with the DRD1
or DRD2 or not), we could not justify increasing the amount of
animals because of ethical reasons.
In sum, the present data indicate that the dopaminergic,
cannabinoid, and opioid systems exert control over the entire
striatum, while the melanocortinergic system specifically targets
the ventral parts. Moreover, we find that the opioid GPCRs have
a preference for expression with either the DRD1 or DRD2 and
that high and low levels of MC4R expression imply coexpres-
sion with DRD1 and DRD2, respectively. Hereby, we expand
the list of GPCRs that are preferentially expressed in one of the
MSN populations and offer some understanding of the molecular
mechanisms that enable the selection of adaptive behaviors.
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FIGURE 4 | Coexpression of the opiate receptors with both DRD1 and
DRD2. (A–F) Example of staining in the striatum. Nuclei were stained using
DAPI (blue). Coexpression depicted in red and green for the described
receptors. White bar, 25μm. (A,D) Coexpression for DRD1 and mu-opioid
receptor (MOR), also for DRD2 and MOR. (B,E) Coexpression for DRD2 and
delta-opioid receptor (DOR), none found for DRD1 and DOR. (C,F)
Coexpression for DRD1 and kappa-opioid receptor (KOR), and some
coexpression for DRD2 and KOR. (G,I,K) Quantification of coexpression of
DRD1, DRD2, MOR, DOR and KOR. Bars
(Continued)
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represent the mean percentage (+s.e.m.) of DAPI stained nuclei that are
positive for DRD1, DRD2, MOR, DOR, or KOR, where “&” indicates a
significant difference of p < 0.05 in the mean percentage of DRD1 positive
cells compared to DRD2 positive cells (as determined by the Mann–Whitney
U test). (H,J,L) Quantification of coexpression of DRD1 or DRD2 and MOR,
DOR, or KOR. Bars represent the mean percentage (+s.e.m.) of cells
expressing DRD1 also expressing DRD2, the percentage of DRD1
expressing cells also expressing MOR, DOR, or KOR and the percentage
of DRD2 expressing cells also expressing MOR, DOR, or KOR, where “∗”
indicate significant differences of p ≤ 0.05 in the percentage of cells
that coexpress DRD1 and MOR, DOR or KOR compared to cells that
coexpress DRD2 and MOR, DOR, or KOR (as determined by the
Mann–Whitney U test).
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